Novel Antitubercular 6-Dialkylaminopyrimidine Carboxamides from Phenotypic Whole-Cell High Throughput Screening of a SoftFocus Library: Structure–Activity Relationship and Target Identification Studies
暂无分享,去创建一个
G. Drewes | C. Harris | Markus Boesche | K. Chibale | Dale Taylor | P. V. van Helden | J. Lelièvre | V. Mizrahi | D. Warner | S. Ghidelli-Disse | C. Barry | H. Boshoff | M. Lafuente-Monasterio | Aloysius T. Nchinda | Gracia Santos | Lluís Ballell | María José Rebollo-López | L. Street | Mathew Njoroge | F. Sirgel | S. Simelane | R. Seldon | Candice Soares de Melo | R. Gessner | Atica Moosa | N. Lawrence | Richard Gordon | Beatriz Urones | Colin R. Wilson | S. Ghorpade | R. Mueller | E. Abay | C. Brunschwig | H. Pflaumer | O. Sanz | C. Selenski | Matthew Axtman | Christel Brunschwig | D. Taylor | Paul van Helden | Sandile B. Simelane
[1] T. Ioerger,et al. Susceptibility of Mycobacterium tuberculosis Cytochrome bd Oxidase Mutants to Compounds Targeting the Terminal Respiratory Oxidase, Cytochrome c , 2017, Antimicrobial Agents and Chemotherapy.
[2] Thomas R. Ioerger,et al. Essential but Not Vulnerable: Indazole Sulfonamides Targeting Inosine Monophosphate Dehydrogenase as Potential Leads against Mycobacterium tuberculosis. , 2017, ACS infectious diseases.
[3] G. Poce,et al. MmpL3 is the flippase for mycolic acids in mycobacteria , 2017, Proceedings of the National Academy of Sciences.
[4] D. Schnappinger,et al. Validation of CoaBC as a Bactericidal Target in the Coenzyme A Pathway of Mycobacterium tuberculosis , 2016, ACS infectious diseases.
[5] Robert H Bates,et al. Identification of KasA as the cellular target of an anti-tubercular scaffold , 2016, Nature Communications.
[6] V. Mizrahi,et al. Bioluminescent Reporters for Rapid Mechanism of Action Assessment in Tuberculosis Drug Discovery , 2016, Antimicrobial Agents and Chemotherapy.
[7] P. Wyatt,et al. Prediction of Drug Penetration in Tuberculosis Lesions. , 2016, ACS infectious diseases.
[8] Richard E. Lee,et al. New agents for the treatment of drug-resistant Mycobacterium tuberculosis. , 2016, Advanced drug delivery reviews.
[9] J. Heyckendorf,et al. Personalized medicine for patients with MDR-TB. , 2016, The Journal of antimicrobial chemotherapy.
[10] G. Drewes,et al. THPP target assignment reveals EchA6 as an essential fatty acid shuttle in mycobacteria , 2016, Nature Microbiology.
[11] C. Harris,et al. Aminopyrazolo[1,5-a]pyrimidines as potential inhibitors of Mycobacterium tuberculosis: Structure activity relationships and ADME characterization. , 2015, Bioorganic & medicinal chemistry.
[12] Paul W Smith,et al. Perspective: Challenges and opportunities in TB drug discovery from phenotypic screening. , 2015, Bioorganic & medicinal chemistry.
[13] P. Karakousis,et al. Future target-based drug discovery for tuberculosis? , 2014, Tuberculosis.
[14] V. Mizrahi,et al. Shortening treatment for tuberculosis--to basics. , 2014, The New England journal of medicine.
[15] Tom L. Blundell,et al. Respiratory Flexibility in Response to Inhibition of Cytochrome c Oxidase in Mycobacterium tuberculosis , 2014, Antimicrobial Agents and Chemotherapy.
[16] Christopher B. Cooper,et al. 1,4-Azaindole, a Potential Drug Candidate for Treatment of Tuberculosis , 2014, Antimicrobial Agents and Chemotherapy.
[17] Bart Hens,et al. A review of drug solubility in human intestinal fluids: implications for the prediction of oral absorption. , 2014, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[18] Marcus Bantscheff,et al. Ion coalescence of neutron encoded TMT 10-plex reporter ions. , 2014, Analytical chemistry.
[19] T. Buclin,et al. Towards a new combination therapy for tuberculosis with next generation benzothiazinones , 2014, EMBO molecular medicine.
[20] S. Cole,et al. Tuberculosis drug discovery in the post-post-genomic era , 2014, EMBO molecular medicine.
[21] Vijay T. Ahuja,et al. Azaindoles: noncovalent DprE1 inhibitors from scaffold morphing efforts, kill Mycobacterium tuberculosis and are efficacious in vivo. , 2013, Journal of medicinal chemistry.
[22] Se Yeon Kim,et al. Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis , 2013, Nature Medicine.
[23] D. Menzies,et al. A Review of the Evidence for Using Bedaquiline (TMC207) to Treat Multi-Drug Resistant Tuberculosis , 2013, Infectious Diseases and Therapy.
[24] N. Leadbeater,et al. A Weinreb amide approach to the synthesis of trifluoromethylketones. , 2012, Chemical communications.
[25] K. Andries,et al. Discovery and development of SQ109: a new antitubercular drug with a novel mechanism of action. , 2012, Future microbiology.
[26] L. Dover,et al. Current status and research strategies in tuberculosis drug development. , 2011, Journal of medicinal chemistry.
[27] C. Harris,et al. The Design and Application of Target-Focused Compound Libraries , 2011, Combinatorial chemistry & high throughput screening.
[28] W. Ren,et al. Mo(CO)6‐Mediated Carbamoylation of Aryl Halides. , 2011 .
[29] P. Grandi,et al. Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes , 2011, Nature Biotechnology.
[30] G. D. de Souza,et al. Definition of novel cell envelope associated proteins in Triton X-114 extracts of Mycobacterium tuberculosis H37Rv , 2010, BMC Microbiology.
[31] J. Falgueyret,et al. The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K. , 2008, Bioorganic & medicinal chemistry letters.
[32] D. Speijer,et al. 1,2,3-Triazoles as peptide bond isosteres: synthesis and biological evaluation of cyclotetrapeptide mimics. , 2007, Organic & biomolecular chemistry.
[33] Hinrich W. H. Göhlmann,et al. A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis , 2005, Science.
[34] C Antzelevitch,et al. The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology. , 2000, European heart journal.
[35] K Gubernator,et al. Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes. , 1998, Journal of medicinal chemistry.
[36] L. Soto-Ramírez,et al. [Treatment of tuberculosis]. , 1997, Gaceta medica de Mexico.